Q32 Bio Inc Dossier
Qualitative Analysis
Business overview
Q32 Bio Inc. (formerly Homology Medicines, Inc.) is a clinical-stage biotechnology company focused on developing novel biologics designed to restore healthy immune balance in patients suffering from severe autoimmune and inflammatory diseases. The company's lead product candidate is bempikibart (ADX-914), a fully human anti-interleukin-7 receptor alpha (IL-7Ŕ̴̵̶̷̸̡̢̧̨̛̖̗̘̙̜̝̞̟̠̣̤̥̦̩̪̫̬̭̮̯̰̱̲̳̹̺̻̼͇͈͉͍͎̂̃̄̅̆̇̈̉̊̋̌̍̎̏̐̑̒̓̔̽̾̿̀́͂̓̈́͆͊͋͌̕̚ͅ͏͓͔͕͖͙͚͐͑͒͗͛ͣͤͥͦͧͨͩͪͫͬͭͮͯ͘͜͟͢͝͞͠͡ͰͱͲͳʹ͵Ͷͷͺͻͼͽ;Ϳ΄΅Ά·ΈΉΊΌΎΏΐΑΒΓΔΕΖΗΘΙΚΛΜΝΞΟΠΡΣΤΥΦΧΨΩΪΫάέήίΰα) antagonist monoclonal antibody. Bempikibart is designed to re-regulate adaptive immune function by blocking signaling mediated by both IL-7 and thymic stromal lymphopoietin (TSLP). It is currently being evaluated in Phase 2 clinical trials for the treatment of severe alopecia areata (AA) and has previously completed Phase 2a evaluation in atopic dermatitis (AD). Additionally, Q32 Bio maintains a tissue-targeted complement platform, including ADX-096, which is designed for tissue-targeted complement inhibition across a range of indications.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A strategic restructuring to focus resources on the development of bempikibart for alopecia areata, while pausing other internal programs and reducing headcount. Q32 Bio regained full worldwide development and commercial rights to bempikibart from Amgen.
Expected impact: Extended the company's cash runway and focused clinical development efforts on the high-potential alopecia areata indication.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To complete a reverse merger, enabling Q32 Bio to become a publicly traded company on Nasdaq and securing significant capital to fund its clinical pipeline.
Financial impact: Brought post-transaction cash, cash equivalents, and investments of approximately $130 million (including a concurrent $42 million private placement) to fund operations.
Strategic Partnerships
Divestment of the ADX-097 program (a tissue-targeted complement inhibitor) to monetize the asset and provide non-dilutive funding to support the development of bempikibart.
Terms: $7.0 million upfront payment at closing, $3.0 million payment on the six-month anniversary of closing, a $2.0 million near-term milestone, and eligibility for up to $580 million in future development, regulatory, and commercial milestones, plus tiered royalties.